This site is intended for healthcare professionals

FDA accepts re-submitted NDA for ACER 001 to treat patients with urea cycle disorders

Read time: 1 mins
Published:29th Jul 2022

Acer Therapeutics Inc. and its collaboration partner, Relief Therapeutics Holding SA announced the FDA has accepted for review Acer’s resubmitted New Drug Application (NDA) for ACER 001 (sodium phenylbutyrate) for oral suspension for the treatment of patients with urea cycle disorders (UCDs)

The FDA designated the NDA as a Class 2 resubmission and set a Prescription Drug User Fee Act (PDUFA) target action date of January 15, 2023.

In June 2022, as previously announced, the FDA issued Acer a Complete Response Letter (CRL) stating that satisfactory inspection of Acer’s third-party contract packaging manufacturer is required before the ACER 001 NDA may be approved. Acer notified the FDA in the NDA resubmission that the third-party contract packaging manufacturer is ready for inspection. The FDA did not cite any other approvability issues in the CRL pertaining to the NDA, nor request any additional clinical or pharmacokinetic studies be conducted prior to FDA action. Additional existing nonclinical information as requested by the FDA in the CRL but identified as “not an approvability issue”, as well as labeling and other required updates to the original NDA, were provided in the resubmission of the NDA.

Condition: Urea Cycle Disorders
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.